Clinical Scorecard: Epiretinal Membrane Removal May Reduce Injection Burden in nAMD
At a Glance
| Category | Detail |
|---|---|
| Condition | neovascular age-related macular degeneration (nAMD) |
| Key Mechanisms | Removal of epiretinal membrane (ERM) may alleviate cystoid macular edema contributing to treatment resistance. |
| Target Population | Patients with nAMD and coexisting ERM. |
| Care Setting | Retina specialty clinic. |
Key Highlights
- Two-thirds of patients stopped or reduced anti-VEGF injections post-surgery.
- Mean number of injections decreased from 7.58 to 4.33 after ERM removal.
- Four patients stopped injections, four had a reduced injection burden.
- Central retinal thickness decreased from 328 μm to 288 μm post-surgery.
- Visual acuity changes were not statistically significant.
Guideline-Based Recommendations
Diagnosis
- Evaluate for coexisting ERM in patients with treatment-resistant nAMD.
Management
- Consider vitrectomy with ERM removal for patients with persistent cystoid macular edema despite anti-VEGF therapy.
Monitoring & Follow-up
- Monitor injection frequency and visual acuity post-surgery.
Risks
- Limited by small sample size and single-provider treatment.
Patient & Prescribing Data
Patients with neovascular age-related macular degeneration and epiretinal membrane.
Surgery may reduce the burden of anti-VEGF injections.
Clinical Best Practices
- Assess the presence of ERM in patients with nAMD.
- Discuss potential benefits and risks of surgical intervention with patients.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.